HCV/HIV treatment outcomes 0 25 50 75 100 G1G2/3 Monoinfection APRICOT ACTG RIBAVIC Laguno et al.
{"Image DocumentName": "HCV/HIV treatment outcomes", "Image ImageDescription": "Genotype 1 SVR 14\u201338% Genotype 3 SVR 44\u201373% Monoinfection. APRICOT. SVR (%) ACTG. 50. RIBAVIC. Laguno et al. PRESCO. 25. Outline studies. G1. G2/3. Genotype. Fried et al, NEJM 2002, 347: , Torriani et al, NEJM 2004; 351: , Chung R, et al, NEJM 2004: 351; 451-9, Carrat F, et al, JAMA 2004: 292: , Laguno et al, AIDS 2004; 18: F27-F36, Nunez et al, JAIDS 2007: 45:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}